AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orion Oyj

Report Publication Announcement Jul 17, 2020

3232_fs_2020-07-17_7cd88a95-7732-4c9d-b4a2-20c65c0034c2.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Disclosure 385664

Orion - Financial Calendar

Orion Corporation's financial reporting and Annual General Meeting in 2021

ORION CORPORATION STOCK EXCHANGE RELEASE 17 JULY 2020 at 9.30 EEST

**Orion Corporation's financial reporting and Annual General Meeting in 2021

**

Orion Corporation will publish its Financial Statement Release 2020 on Tuesday, 9 February 2021.

The publication dates of the Interim Reports and the Half-Year Financial Report in 2021 are as follows:

Interim Report January-March 2021

Half-Year Financial Report January-June 2021

Interim Report January-September 2021
Tuesday, 27 April 2021

Monday, 19 July 2021

Wednesday, 20 October 2021

The Financial Statements and the Report of the Board of Directors for 2020 will be published on the Company's website at the latest in week 9/2021.

The Annual General Meeting is planned to be held on Thursday, 25 March 2021 in Helsinki.

Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases.

Orion Corporation

Timo Lappalainen

President and CEO
Olli Huotari

SVP, Corporate Functions

Contact person:

Tuukka Hirvonen, Investor Relations

tel. +358 10 426 2721

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Talk to a Data Expert

Have a question? We'll get back to you promptly.